Cardinal Health expects growth to normalize in fiscal 2027 after fiscal 2026 delivered double-digit earnings growth in all five operating segments, CEO Jason Hollar said at a Baird event. Hollar said the prior year's outperformance was driven by strong healthcare utilization, specialty growth, new customer wins, acquisitions and operational execution, and that unusually strong specialty growth and customer onboarding will be less pronounced in fiscal 2027. Cardinal's specialty business grew 25% in fiscal 2026, and the company is expanding its specialty and at-home strategy through three managed-services organization platforms focused on oncology, urology and gastroenterology, plus bolt-on acquisitions, including four completed in the most recent quarter. The Strive Medical acquisition has closed, while the purchase of AdaptHealth's diabetes business is expected to close in the second half of fiscal 2027, expanding Cardinal's continuous glucose monitoring presence; Hollar noted only 35% of people eligible for a CGM through insurance coverage actually have one. Cardinal plans to add three more automated distribution centers for small-parcel shipping of higher-value at-home products, and Hollar said cash flow was strong in fiscal 2026, putting the company about 90% of the way toward its previously announced $10 billion objective.
Cardinal Health IncCardinal Health reported double-digit earnings growth in all five segments in fiscal 2026 and is about 90% toward its $10 billion cash flow objective, though it expects growth to normalize in fiscal 2027.
Adapthealth CorpCardinal Health's purchase of AdaptHealth's diabetes business is expected to close in the second half of fiscal 2027, a divestiture mentioned only as context.
